Randomised trial of pembrolizumab versus standard treatment in patients with recurrent or metastatic head and neck cancer

Bookmark and Share
Published: 1 Jun 2015
Views: 2342
Rating:
Save
Dr Kevin Harrington - Institute of Cancer Research, London, UK

Dr Harrington talks to ecancertv at ASCO 2015 about a phase III randomised trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer.